JSW, B., TJ, v. W., KA, G., T, R., EME, V., DJAR, M., . . . D, v. d. W. (2024). Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma. Journal for immunotherapy of cancer, 12(6), . https://doi.org/10.1136/jitc-2024-009215
Chicago Style (17th ed.) CitationJSW, Borgers, et al. "Autoantibody-positivity Before and Seroconversion During Treatment with Anti-PD-1 Is Associated with Immune-related Adverse Events in Patients with Melanoma." Journal for Immunotherapy of Cancer 12, no. 6 (2024). https://doi.org/10.1136/jitc-2024-009215.
MLA (9th ed.) CitationJSW, Borgers, et al. "Autoantibody-positivity Before and Seroconversion During Treatment with Anti-PD-1 Is Associated with Immune-related Adverse Events in Patients with Melanoma." Journal for Immunotherapy of Cancer, vol. 12, no. 6, 2024, https://doi.org/10.1136/jitc-2024-009215.
